AUPH Relative Valuation
AUPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AUPH is overvalued; if below, it's undervalued.
Historical Valuation
Aurinia Pharmaceuticals Inc (AUPH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.86 is considered Undervalued compared with the five-year average of 0.37. The fair price of Aurinia Pharmaceuticals Inc (AUPH) is between 94.44 to 96.06 according to relative valuation methord. Compared to the current price of 11.09 USD , Aurinia Pharmaceuticals Inc is Undervalued By 88.26%.
Relative Value
Fair Zone
94.44-96.06
Current Price：11.09
88.26%
Undervalued
16.31
PE
1Y
3Y
5Y
Trailing
Forward
8.28
EV/EBITDA
Aurinia Pharmaceuticals Inc. (AUPH) has a current EV/EBITDA of 8.28. The 5-year average EV/EBITDA is 1.81. The thresholds are as follows: Strongly Undervalued below -83.03, Undervalued between -83.03 and -40.61, Fairly Valued between 44.22 and -40.61, Overvalued between 44.22 and 86.64, and Strongly Overvalued above 86.64. The current Forward EV/EBITDA of 8.28 falls within the Historic Trend Line -Fairly Valued range.
11.06
EV/EBIT
Aurinia Pharmaceuticals Inc. (AUPH) has a current EV/EBIT of 11.06. The 5-year average EV/EBIT is -41.64. The thresholds are as follows: Strongly Undervalued below -378.08, Undervalued between -378.08 and -209.86, Fairly Valued between 126.59 and -209.86, Overvalued between 126.59 and 294.81, and Strongly Overvalued above 294.81. The current Forward EV/EBIT of 11.06 falls within the Historic Trend Line -Fairly Valued range.
4.86
PS
Aurinia Pharmaceuticals Inc. (AUPH) has a current PS of 4.86. The 5-year average PS is 14.17. The thresholds are as follows: Strongly Undervalued below -22.42, Undervalued between -22.42 and -4.12, Fairly Valued between 32.46 and -4.12, Overvalued between 32.46 and 50.75, and Strongly Overvalued above 50.75. The current Forward PS of 4.86 falls within the Historic Trend Line -Fairly Valued range.
9.91
P/OCF
Aurinia Pharmaceuticals Inc. (AUPH) has a current P/OCF of 9.91. The 5-year average P/OCF is -8.19. The thresholds are as follows: Strongly Undervalued below -62.17, Undervalued between -62.17 and -35.18, Fairly Valued between 18.80 and -35.18, Overvalued between 18.80 and 45.79, and Strongly Overvalued above 45.79. The current Forward P/OCF of 9.91 falls within the Historic Trend Line -Fairly Valued range.
22.09
P/FCF
Aurinia Pharmaceuticals Inc. (AUPH) has a current P/FCF of 22.09. The 5-year average P/FCF is -4.73. The thresholds are as follows: Strongly Undervalued below -126.26, Undervalued between -126.26 and -65.50, Fairly Valued between 56.03 and -65.50, Overvalued between 56.03 and 116.80, and Strongly Overvalued above 116.80. The current Forward P/FCF of 22.09 falls within the Historic Trend Line -Fairly Valued range.
Aurinia Pharmaceuticals Inc (AUPH) has a current Price-to-Book (P/B) ratio of 4.15. Compared to its 3-year average P/B ratio of 2.88 , the current P/B ratio is approximately 44.28% higher. Relative to its 5-year average P/B ratio of 3.92, the current P/B ratio is about 5.76% higher. Aurinia Pharmaceuticals Inc (AUPH) has a Forward Free Cash Flow (FCF) yield of approximately 6.69%. Compared to its 3-year average FCF yield of -3.00%, the current FCF yield is approximately -323.19% lower. Relative to its 5-year average FCF yield of -4.38% , the current FCF yield is about -252.84% lower.
4.15
P/B
Median3y
2.88
Median5y
3.92
6.69
FCF Yield
Median3y
-3.00
Median5y
-4.38
Competitors Valuation Multiple
The average P/S ratio for AUPH's competitors is 167.01, providing a benchmark for relative valuation. Aurinia Pharmaceuticals Inc Corp (AUPH) exhibits a P/S ratio of 4.86, which is -97.09% above the industry average. Given its robust revenue growth of 138.81%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AUPH increased by 54.04% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 1.26 to 15.75.
The secondary factor is the Revenue Growth, contributed 138.81%to the performance.
Overall, the performance of AUPH in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Aurinia Pharmaceuticals Inc (AUPH) currently overvalued or undervalued?
What is Aurinia Pharmaceuticals Inc (AUPH) fair value?
How does AUPH's valuation metrics compare to the industry average?
What is the current P/B ratio for Aurinia Pharmaceuticals Inc (AUPH) as of Aug 05 2025?
What is the current FCF Yield for Aurinia Pharmaceuticals Inc (AUPH) as of Aug 05 2025?
What is the current Forward P/E ratio for Aurinia Pharmaceuticals Inc (AUPH) as of Aug 05 2025?